ATOS
Price
$5.27
Change
-$0.26 (-4.70%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
47.62M
56 days until earnings call
Intraday BUY SELL Signals
BDTX
Price
$2.40
Change
-$0.13 (-5.16%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
143.58M
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATOS vs BDTX

Header iconATOS vs BDTX Comparison
Open Charts ATOS vs BDTXBanner chart's image
Atossa Therapeutics
Price$5.27
Change-$0.26 (-4.70%)
Volume$1.01K
Capitalization47.62M
Black Diamond Therapeutics
Price$2.40
Change-$0.13 (-5.16%)
Volume$33.2K
Capitalization143.58M
ATOS vs BDTX Comparison Chart in %
ATOS
Daily Signal:
Gain/Loss:
BDTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATOS vs. BDTX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and BDTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ATOS: $5.53 vs. BDTX: $2.52)
Brand notoriety: ATOS and BDTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 459% vs. BDTX: 99%
Market capitalization -- ATOS: $47.62M vs. BDTX: $143.58M
ATOS [@Biotechnology] is valued at $47.62M. BDTX’s [@Biotechnology] market capitalization is $143.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileBDTX’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • BDTX’s FA Score: 0 green, 5 red.
According to our system of comparison, BDTX is a better buy in the long-term than ATOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 4 TA indicator(s) are bullish while BDTX’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 4 bullish, 5 bearish.
  • BDTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, BDTX is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -46.16% price change this week, while BDTX (@Biotechnology) price change was -2.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

ATOS is expected to report earnings on Apr 01, 2026.

BDTX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BDTX($144M) has a higher market cap than ATOS($47.6M). BDTX YTD gains are higher at: 3.704 vs. ATOS (-37.514). BDTX has higher annual earnings (EBITDA): 12.2M vs. ATOS (-32.84M). ATOS has less debt than BDTX: ATOS (0) vs BDTX (19.7M). BDTX has higher revenues than ATOS: BDTX (70M) vs ATOS (0).
ATOSBDTXATOS / BDTX
Capitalization47.6M144M33%
EBITDA-32.84M12.2M-269%
Gain YTD-37.5143.704-1,013%
P/E RatioN/A6.81-
Revenue070M-
Total CashN/A136M-
Total Debt019.7M-
FUNDAMENTALS RATINGS
ATOS vs BDTX: Fundamental Ratings
ATOS
BDTX
OUTLOOK RATING
1..100
6169
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9746
PRICE GROWTH RATING
1..100
9663
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (14) in the Medical Specialties industry is somewhat better than the same rating for BDTX (49) in the null industry. This means that ATOS’s stock grew somewhat faster than BDTX’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BDTX (100) in the null industry. This means that ATOS’s stock grew similarly to BDTX’s over the last 12 months.

BDTX's SMR Rating (46) in the null industry is somewhat better than the same rating for ATOS (97) in the Medical Specialties industry. This means that BDTX’s stock grew somewhat faster than ATOS’s over the last 12 months.

BDTX's Price Growth Rating (63) in the null industry is somewhat better than the same rating for ATOS (96) in the Medical Specialties industry. This means that BDTX’s stock grew somewhat faster than ATOS’s over the last 12 months.

BDTX's P/E Growth Rating (99) in the null industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that BDTX’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSBDTX
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signal:
Gain/Loss:
BDTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LRDC0.880.01
+1.62%
Laredo Oil, Inc
AIBGY23.050.09
+0.39%
AIB Group PLC
JXFGF0.29N/A
N/A
JINXIN FERTILITY GROUP LTD.
ROYUF73.11N/A
N/A
Royal Unibrew A S
AGXTF0.04N/A
N/A
ARGENTEX GROUP PLC

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with AXON. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-1.07%
AXON - ATOS
42%
Loosely correlated
-1.89%
RGNX - ATOS
40%
Loosely correlated
+0.74%
BEAM - ATOS
38%
Loosely correlated
-0.11%
BDTX - ATOS
37%
Loosely correlated
-0.79%
VYGR - ATOS
37%
Loosely correlated
-2.25%
More

BDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BDTX has been loosely correlated with NUVL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BDTX jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BDTX
1D Price
Change %
BDTX100%
-0.79%
NUVL - BDTX
46%
Loosely correlated
+2.12%
BEAM - BDTX
46%
Loosely correlated
-0.11%
IMCR - BDTX
45%
Loosely correlated
-2.94%
CRBU - BDTX
45%
Loosely correlated
+6.85%
DNLI - BDTX
44%
Loosely correlated
-4.22%
More